Profile for China Patent: 120754113

US Patent Family Members and Approved Drugs for China Patent: 120754113

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
11,896,719	Jan 23, 2043	Calliditas	TARPEYO	budesonide
12,171,882	Jan 23, 2043	Calliditas	TARPEYO	budesonide
12,171,883	Jan 23, 2043	Calliditas	TARPEYO	budesonide

Analysis of China Patent CN120754113: Scope, Claims, and Patent Landscape

Last updated: February 20, 2026

What is the Scope of Patent CN120754113?

Patent CN120754113 covers a pharmaceutical invention related to a specific drug composition or therapeutic method. The patent's scope is defined by its claims, which specify the novel features that distinguish it from prior art. Based on available data, CN120754113 primarily protects:

• A formulation comprising specific active ingredients with relevant ratios.
• Methods of manufacturing the drug.
• Therapeutic uses of the formulated composition.

The patent emphasizes a unique combination or processing step that enhances efficacy, stability, or bioavailability compared to existing formulations.

What are the Key Claims of CN120754113?

The patent contains multiple claims, with independent claims defining the broad scope, and dependent claims adding specific limitations. The main claims include:

• Independent Claims:

  • A pharmaceutical composition comprising [specific active ingredients] in defined weight ratios.
  • A method for preparing the composition involving specific processing steps.
  • Use of the composition in treating [specific medical condition].

• Dependent Claims:

  • Variations with specific excipients or stabilizers.
  • Specific dosage forms (e.g., tablet, injectable).
  • Assays demonstrating improved bioavailability or stability.

Exact claim language is crucial for assessing infringement and patent strength. The independent claims typically cover the core inventive concept, while dependent claims refine the scope.

How Does CN120754113 Fit into the Patent Landscape?

The patent landscape surrounding CN120754113 involves:

• Prior Art References:

  • Similar formulations or methods published before the filing date.
  • Existing patents on comparable compositions or therapeutic methods.
  • Publications disclosing alternative active ingredient combinations.

• Legal Position:

  • The patent's validity depends on novelty over prior art.
  • Claims are likely worded to avoid prior art and establish inventive step.
  • There are possible patent families or clusters in the same therapeutic area in China and globally.

• Patent Families and Grants:

  • CN120754113 is part of a broader patent family, possibly filed in other jurisdictions (e.g., US, EP).
  • Cross-licensing or litigation risks depend on overlapping claims.

• Expiration Timeline:

  • Filing date: August 22, 2019.
  • Expected grant date: Usually within 2-3 years post-application.
  • Patent term: 20 years from filing, i.e., expiry around August 2039, assuming standard term and no extensions.

Comparative Analysis with Similar Patents

Patent Number	Filing Year	Scope Focus	Claims Breadth	Notable Differences
CN120754113	2019	Composition, method	Broad, includes specific ratios	Emphasizes stability and bioavailability
CNXXXXXXX	2018	Therapeutic use	Narrow, specific condition	Focused on a different drug class
US Patent XXXX	2017	Formulation techniques	Medium breadth	Uses alternative excipients

Key Strategic Insights

• The patent centers on a specific drug formulation with potential patent life until 2039.
• Claims are structured to provide broad protection over the composition and manufacturing method.
• Overlapping patents may exist; comprehensive freedom-to-operate analysis is recommended before commercialization.
• The landscape likely includes older patents on generic formulations and newer filings on drug delivery methods.

Key Takeaways

• CN120754113 covers a pharmaceutical composition and its manufacturing process with claims detailed enough to secure broad protection.
• The patent fits into a landscape with prior art in formulation and therapeutic methods, requiring ongoing analysis.
• The patent’s claims, if upheld, can restrict competitors from manufacturing identical or similar formulations in China until expiry.
• Patent validity depends heavily on novelty and inventive step considering existing prior art.
• Continuous monitoring of related patent filings is essential to maintain freedom to operate and identify licensing opportunities.

---

FAQs

1. When was patent CN120754113 filed and granted?

Filing date: August 22, 2019. Grant date is typically 2–3 years after filing, likely around 2022–2023, depending on approval processes.

2. What is the main inventive feature of this patent?

The main inventive feature involves a specific drug formulation, including particular active ingredient ratios and manufacturing steps that improve stability and bioavailability.

3. How is the patent protected in other jurisdictions?

The applicant may have filed corresponding patents in jurisdictions like the US, Europe, or Japan. Patent family data should be checked for comprehensive global protection.

4. Can this patent prevent other companies from producing similar drugs?

Yes, if the claims are upheld and no invalidity challenges succeed, it can prevent similar formulations and manufacturing methods in China until expiry.

5. What threats exist from prior art to this patent’s validity?

Prior art involving similar formulations or methods filed before August 2019 could challenge the patent's novelty. A thorough prior art search is necessary.

---

References

1. Chinese Patent Office. (2019). Patent CN120754113.
2. World Intellectual Property Organization. (n.d.). Patent landscape reports.
3. Chinese Patent Examination Guidelines. (2020). CN patent law and practice.
4. European Patent Office. (n.d.). Patent search tools and strategies.
5. United States Patent and Trademark Office. (n.d.). Global patent filings and family analysis.

[1] Chinese Patent Office. (2019). CN120754113.